



RECEIVED
REGION 1

Purdue Pharma L.P.

'04 DEC 23 A 7:12

6 Cedar Brook Drive
Cranbury, New Jersey 08512

December 21, 2004

Licensing Assistance Section
Nuclear Materials Safety Branch
U.S. Nuclear Regulatory Commission, Region I
475 Allendale Road
King of Prussia, PA 19406-1415

03035882

Re: ***NRC License # 29-30698-01***
Purdue Pharma LP
Cranbury, New Jersey Facility

Dear Sir/Madam:


Please consider this correspondence as notification that Purdue Pharma L.P. requests an amendment to our existing NRC Radioactive Materials License # 29-30698-01. We request the following changes to our license:

1. Purdue's Discovery Research activities located in Cranbury, NJ have been significantly reduced in size. The company will consolidate its research activities into one wing of the building. As a result of this consolidation, radioactive material will now be handled in one new lab and a new waste storage area that previously were general use areas. The enclosed floor plan illustrates the new lab and new waste storage area where radioactive material will be handled. These are the only locations in the facility where radioactive material will be handled.
2. The reduction in research activities has also resulted in a reduction in headcount. Several researchers listed in Section 11 A on our license are no longer with Purdue. The following individuals should be deleted from section 11 A: Dr. Earl Albone, Dr. Marc Berger, Dr. Charlie Chen and Dr. Mohamed Hachicha.

To help expedite our request please do not hesitate to contact me at 609-409-5826 or by fax at 609-409-5799. Your time and assistance in this matter is appreciated.

Mathew L. Swan, CIH, CSP
Director, Environment, Health & Safety

136183
NMSS/RGNI MATERIALS-032



This is to acknowledge the receipt of your letter/application dated

12/21/2004, and to inform you that the initial processing which includes an administrative review has been performed.

Amended. 29-30698-01
There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 136183.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.

BETWEEN:

License Fee Management Branch, ARM
and
Regional Licensing Sections

: (FOR LFMS USE)
: INFORMATION FROM LTS
: -----
:
: Program Code: 03620
: Status Code: 0
: Fee Category: 3E 3M
: Exp. Date: 20120131
: Fee Comments: _____
: Decom Fin Assur Req: N
: ::::::::::::::::::::::::::::::::::::::

LICENSE FEE TRANSMITTAL

A. REGION I

1. APPLICATION ATTACHED

Applicant/Licensee: PURDUE PHARMA, L.P.
Received Date: 20041223
Docket No: 3035882
Control No.: 136183
License No.: 29-30698-01
Action Type: Amendment

2. FEE ATTACHED

Amount: /
Check No.: /

3. COMMENTS

Signed M. A. Perkins
Date 12/23/04

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered /__/)

1. Fee Category and Amount: _____

2. Correct Fee Paid. Application may be processed for:

Amendment _____
Renewal _____
License _____

3. OTHER _____

Signed _____
Date _____